# Conditioning regimen (myeloablative, reduced-intensity)

Source: https://onco.cc/terms/conditioning-regimen/  
OnCo record `conditioning-regimen` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The chemotherapy (with or without whole-body radiation) given in the days before a stem cell transplant to destroy the diseased marrow and, for donor transplants, suppress the patient's immune system so the graft is not rejected.

## Summary

Myeloablative conditioning (busulfan-cyclophosphamide, cyclophosphamide-TBI, high-dose melphalan for myeloma, BEAM for lymphoma) gives maximal anti-leukaemic effect but is tolerable only under about 60; reduced-intensity and non-myeloablative regimens (fludarabine-based, low-dose TBI, treosulfan) rely on the donor immune effect and have extended allogeneic transplant to older patients at the cost of higher relapse. Regimen choice is a trade-off between relapse and toxicity (mucositis, organ damage, infertility, veno-occlusive disease). Lymphodepletion before CAR-T is a milder cousin of the same idea.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: conditioning; conditioning chemotherapy; conditioning regimen; myeloablative; myeloablative conditioning; reduced-intensity; reduced-intensity conditioning; RIC; non-myeloablative; total body irradiation; TBI; busulfan-cyclophosphamide; BuCy; BuMel; BEAM; fludarabine-based conditioning; treosulfan-based

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens
- Wikipedia: https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens

## Connected records

- terms: [Alkylating agents and antimetabolites](https://onco.cc/terms/alkylating-agent/), [Allogeneic stem cell transplant (allo-SCT)](https://onco.cc/terms/allogeneic-transplant/), [Autologous stem cell transplant (ASCT)](https://onco.cc/terms/autologous-transplant/), [Graft-versus-host disease (GVHD) and graft-versus-leukaemia](https://onco.cc/terms/gvhd/), [Gray unit (Gy)](https://onco.cc/terms/gray-unit/), [Lymphodepletion before CAR-T](https://onco.cc/terms/lymphodepletion/), [Mucositis and stomatitis](https://onco.cc/terms/mucositis/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/), [Treosulfan](https://onco.cc/drugs/treosulfan/)
- technologies: [Bone, eyes, kidneys and lungs after transplant](https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/), [Chronic graft-versus-host disease](https://onco.cc/technologies/gvhd-chronic-overview/), [Fertility, growth and what total body irradiation costs](https://onco.cc/technologies/rejuv-tx-fertility-and-growth/), [Hormones, metabolism and the heart after transplant](https://onco.cc/technologies/rejuv-tx-endocrine-and-cardiometabolic/), [Late effects after a stem cell transplant](https://onco.cc/technologies/rejuv-tx-late-effects-overview/), [Preventing graft-versus-host disease, and what prevention costs](https://onco.cc/technologies/gvhd-prophylaxis/), [Second cancers after allogeneic transplant](https://onco.cc/technologies/rejuv-tx-second-cancers/)
- cancers: [Chronic myeloid leukaemia, accelerated and blast phase](https://onco.cc/cancers/cml-advanced-phase/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/), [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)

---
JSON: https://onco.cc/api/v1/entities/conditioning-regimen.json